COPENHAGEN, Denmark — October 8, 2025 — Leads & Copy — Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, has launched a significant improvement to its AI-platform, AI-Immunology™, with a new automated vaccine design module.
The new module automatically provides vaccine designs for maximum protective immune responses by ensuring optional sequence and conformation of the vaccine targets. These targets – or antigens – can already be identified by AI-Immunology™ meaning the platform can now automatically perform the complete process of target discovery and vaccine design.
Automated design can both improve the quality of the vaccines and shorten the design time compared to manual methods from months to days, also carrying significant cost savings. The new module offers solutions for common problems encountered with traditional manual design methods, namely ensuring that vaccine targets can be properly expressed and obtained in the correct conformations.
According to Birgitte Rønø, CSO and interim CEO of Evaxion, the new modules significantly enhance their value proposition towards potential partners and increase their in-house capabilities. She added that continued development, expansion and refinement of the platform remains a cornerstone of their strategy as a leader in AI-based vaccine discovery and design.
The new design module can be applied to new as well as existing vaccines thereby potentially enabling the development of new and improved generations of vaccines already in use.
Evaxion will present numerous test results confirming the improvement of AI-Immunology™ at the World Vaccine Congress Europe in Amsterdam on October 15, 2025. See presentation details below:
Presentation details:
Title: Antigen optimization for infectious disease vaccines using AI‑Immunology™
Track: 1, Emerging & Infectious Diseases
Date/Time: October 15 at 12.30 CEST
Presenter: Thomas Trolle, PhD, Director, Bioinformatics & AI/ML at Evaxion
Contact information:
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Source: Evaxion A/S
